Alimera Sciences Stock Price, News & Analysis (NASDAQ:ALIM) $3.08 -0.06 (-1.91%) (As of 11/30/2023 ET) Add Compare Share Share Today's Range$2.95▼$3.2850-Day Range$2.63▼$3.5052-Week Range$1.30▼$3.90Volume66,385 shsAverage Volume29,789 shsMarket Capitalization$161.72 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Alimera Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside110.7% Upside$6.50 Price TargetShort InterestBearish0.30% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 2 Articles This WeekInsider TradingAcquiring Shares$1.96 M Bought Last QuarterProj. Earnings Growth-77.78%From $0.54 to $0.12 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.06 out of 5 starsMedical Sector545th out of 948 stocksPharmaceutical Preparations Industry265th out of 444 stocks 3.5 Analyst's Opinion Consensus RatingAlimera Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.50, Alimera Sciences has a forecasted upside of 110.7% from its current price of $3.09.Amount of Analyst CoverageAlimera Sciences has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.30% of the outstanding shares of Alimera Sciences have been sold short.Short Interest Ratio / Days to CoverAlimera Sciences has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Alimera Sciences has recently increased by 2.81%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAlimera Sciences does not currently pay a dividend.Dividend GrowthAlimera Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALIM. Previous Next 2.7 News and Social Media Coverage News SentimentAlimera Sciences has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Alimera Sciences this week, compared to 2 articles on an average week.Search Interest2 people have searched for ALIM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alimera Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,962,810.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders31.40% of the stock of Alimera Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Alimera Sciences are expected to decrease by -77.78% in the coming year, from $0.54 to $0.12 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alimera Sciences is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alimera Sciences is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlimera Sciences has a P/B Ratio of 3.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Alimera Sciences Stock (NASDAQ:ALIM)Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, clinics, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.Read More ALIM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALIM Stock News HeadlinesNovember 29, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Alimera Sciences (NASDAQ:ALIM)November 8, 2023 | finance.yahoo.comAlimera Appoints Maggie A. Pax to Its Board of DirectorsDecember 1, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. October 31, 2023 | finance.yahoo.comAlimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of OphthalmologyOctober 27, 2023 | finance.yahoo.comAlimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Earnings Call TranscriptOctober 27, 2023 | markets.businessinsider.comAlimera Sciences Reports Third Quarter 2023 ResultsOctober 26, 2023 | msn.comAlimera Sciences GAAP EPS of -$0.06 misses by $0.18, revenue of $23.4M beats by $0.68MOctober 26, 2023 | finanznachrichten.deAlimera Sciences, Inc.: Alimera Sciences Reports Third Quarter 2023 ResultsDecember 1, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. October 26, 2023 | finance.yahoo.comAlimera Sciences Inc (ALIM) Reports Q3 2023 Financial ResultsOctober 25, 2023 | msn.comAlimera Sciences Q3 2023 Earnings PreviewOctober 16, 2023 | finance.yahoo.comAlimera Sciences to Report Third Quarter 2023 Financial Results on October 26, 2023, and Provide Corporate UpdateOctober 11, 2023 | finance.yahoo.comAlimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual CongressOctober 6, 2023 | finance.yahoo.comWith 47% ownership, Alimera Sciences, Inc. (NASDAQ:ALIM) has piqued the interest of hedge funds investorsOctober 5, 2023 | benzinga.comBoard Member at Alimera Sciences Acquires Company Stock Options Worth 50,000 SharesOctober 3, 2023 | finanznachrichten.deAlimera Sciences, Inc.: Alimera Sciences Appoints Jason Werner as Chief Operating OfficerOctober 3, 2023 | finance.yahoo.comAlimera Sciences Appoints Jason Werner as Chief Operating OfficerSeptember 14, 2023 | finance.yahoo.comAlimera Sciences, Inc.'s (NASDAQ:ALIM) Profit OutlookSeptember 5, 2023 | finance.yahoo.comAlimera Sciences to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 23, 2023 | finance.yahoo.comAltium Capital Management LP Acquires New Stake in Alimera Sciences IncAugust 18, 2023 | finance.yahoo.comShareholders in Alimera Sciences (NASDAQ:ALIM) are in the red if they invested five years agoAugust 14, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Alimera SciencesAugust 13, 2023 | finance.yahoo.comAlimera Sciences, Inc. (NASDAQ:ALIM) Q2 2023 Earnings Call TranscriptAugust 11, 2023 | finance.yahoo.comStonepine Capital Management, LLC Acquires New Stake in Alimera Sciences IncAugust 11, 2023 | finance.yahoo.comQ2 2023 Alimera Sciences Inc Earnings CallAugust 10, 2023 | finanznachrichten.deAlimera Sciences, Inc.: Alimera Sciences Reports Second Quarter 2023 ResultsAugust 10, 2023 | markets.businessinsider.comHere's what Wall Street expects from Alimera Sciences's earnings reportSee More Headlines Receive ALIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/26/2023Today12/01/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALIM CUSIPN/A CIK1267602 Webwww.alimerasciences.com Phone(678) 990-5740Fax678-990-5744Employees150Year Founded2003Price Target and Rating Average Stock Price Target$6.50 High Stock Price Target$8.00 Low Stock Price Target$5.00 Potential Upside/Downside+110.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.63) Trailing P/E RatioN/A Forward P/E Ratio5.71 P/E GrowthN/ANet Income$-18,110,000.00 Net Margins-29.40% Pretax Margin-29.29% Return on EquityN/A Return on Assets-13.05% Debt Debt-to-Equity Ratio1.31 Current Ratio2.73 Quick Ratio2.63 Sales & Book Value Annual Sales$54.13 million Price / Sales2.99 Cash FlowN/A Price / Cash FlowN/A Book Value$0.93 per share Price / Book3.32Miscellaneous Outstanding Shares52,420,000Free Float35,958,000Market Cap$161.72 million OptionableOptionable Beta1.43 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Richard S. Eiswirth Jr. (Age 55)President, CEO & Director Comp: $597.87kMr. David R. Holland (Age 59)Co-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets Comp: $413.5kDr. Philip Ashman Ph.D. (Age 58)President of International Operations Comp: $389.86kMr. Russell L. Skibsted M.B.A. (Age 64)Senior VP & CFO Mr. Jason WernerChief Operating OfficerChristopher S. VisickVP, General Counsel & SecretaryDr. David Dyer M.D.Chief Retina SpecialistMore ExecutivesKey CompetitorsRigel PharmaceuticalsNASDAQ:RIGLFoghorn TherapeuticsNASDAQ:FHTXStoke TherapeuticsNASDAQ:STOKAkebia TherapeuticsNASDAQ:AKBAPrelude TherapeuticsNASDAQ:PRLDView All CompetitorsInsiders & InstitutionsWorth Venture Partners LLCBought 593,709 shares on 11/15/2023Ownership: 1.133%Stonepine Capital Management LLCBought 3,983,686 shares on 11/14/2023Ownership: 7.600%Tower Research Capital LLC TRC Bought 8,937 shares on 11/14/2023Ownership: 0.023%AIGH Capital Management LLCBought 2,372,572 shares on 11/13/2023Ownership: 4.526%Caligan Partners LpBought 579,000 shares on 9/14/2023Total: $1.96 M ($3.39/share)View All Insider TransactionsView All Institutional Transactions ALIM Stock Analysis - Frequently Asked Questions Should I buy or sell Alimera Sciences stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALIM shares. View ALIM analyst ratings or view top-rated stocks. What is Alimera Sciences' stock price target for 2024? 2 equities research analysts have issued 12 month target prices for Alimera Sciences' stock. Their ALIM share price targets range from $5.00 to $8.00. On average, they expect the company's stock price to reach $6.50 in the next year. This suggests a possible upside of 110.7% from the stock's current price. View analysts price targets for ALIM or view top-rated stocks among Wall Street analysts. How have ALIM shares performed in 2023? Alimera Sciences' stock was trading at $2.71 at the beginning of 2023. Since then, ALIM stock has increased by 13.8% and is now trading at $3.0850. View the best growth stocks for 2023 here. When is Alimera Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our ALIM earnings forecast. How were Alimera Sciences' earnings last quarter? Alimera Sciences, Inc. (NASDAQ:ALIM) released its quarterly earnings data on Thursday, October, 26th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.35. The biopharmaceutical company earned $23.36 million during the quarter, compared to the consensus estimate of $24.40 million. When did Alimera Sciences' stock split? Alimera Sciences shares reverse split on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is Rick Eiswirth's approval rating as Alimera Sciences' CEO? 2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alimera Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB). Who are Alimera Sciences' major shareholders? Alimera Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (7.60%), AIGH Capital Management LLC (4.53%), Worth Venture Partners LLC (1.13%), Tower Research Capital LLC TRC (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adam Morgan, Alto Investors Lp Palo, Caligan Partners Lp, James R Largent, John Philip Jones, Philip Ashman, Richard S Eiswirth Jr and Stanley Morgan. View institutional ownership trends. How do I buy shares of Alimera Sciences? Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ALIM) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alimera Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.